SUPN Supernus Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: SUPN

Price (delayed)

$30.75

Market cap

$1.69B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.29

Enterprise value

$1.66B

Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company markets Trokendi XR® (extended-release topiramate) for ...

Highlights
The debt has dropped by 94% year-on-year
The quick ratio has grown by 34% YoY and by 2.9% from the previous quarter
The EPS has dropped by 130% year-on-year
The company's net income has shrunk by 130% YoY
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.supernus.com
Peers: UTHR ABT LLY BMY

Key stats

What are the main financial stats of SUPN
Market
Shares outstanding
54.97M
Market cap
$1.69B
Enterprise value
$1.66B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.81
Price to sales (P/S)
2.82
EV/EBIT
N/A
EV/EBITDA
20.77
EV/Sales
2.78
Earnings
Revenue
$597.4M
EBIT
-$5.1M
EBITDA
$79.91M
Free cash flow
$99.84M
Per share
EPS
-$0.29
Free cash flow per share
$1.82
Book value per share
$16.98
Revenue per share
$10.9
TBVPS
$11.08
Balance sheet
Total assets
$1.3B
Total liabilities
$374.92M
Debt
$32.99M
Equity
$929.17M
Working capital
$229.77M
Liquidity
Debt to equity
0.04
Current ratio
1.73
Quick ratio
1.42
Net debt/EBITDA
-0.38
Margins
EBITDA margin
13.4%
Gross margin
87.2%
Net margin
-2.6%
Operating margin
-2.7%
Efficiency
Return on assets
-1.2%
Return on equity
-1.7%
Return on invested capital
-2.2%
Return on capital employed
-0.5%
Return on sales
-0.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

SUPN stock price

How has the Supernus Pharmaceuticals stock price performed over time
Intraday
0.23%
1 week
1.65%
1 month
15.08%
1 year
1.85%
YTD
6.25%
QTD
14.95%

Financial performance

How have Supernus Pharmaceuticals's revenue and profit performed over time
Revenue
$597.4M
Gross profit
$520.77M
Operating income
-$16.21M
Net income
-$15.51M
Gross margin
87.2%
Net margin
-2.6%
The company's operating margin has shrunk by 145% QoQ and by 138% YoY
SUPN's operating income has plunged by 139% from the previous quarter and by 134% YoY
The net margin has dropped by 133% year-on-year
The company's net income has shrunk by 130% YoY

Growth

What is Supernus Pharmaceuticals's growth rate over time

Valuation

What is Supernus Pharmaceuticals stock price valuation
SUPN P/E details
P/E
N/A
P/B
1.81
P/S
2.82
EV/EBIT
N/A
EV/EBITDA
20.77
EV/Sales
2.78
The EPS has dropped by 130% year-on-year
SUPN's price to book (P/B) is 4.7% less than its 5-year quarterly average of 1.9
Supernus Pharmaceuticals's revenue has decreased by 11% YoY
The P/S is 4.1% above the 5-year quarterly average of 2.7 and 4.1% above the last 4 quarters average of 2.7

Efficiency

How efficient is Supernus Pharmaceuticals business performance
The return on sales has dropped by 200% since the previous quarter and by 110% year-on-year
The return on assets has dropped by 140% year-on-year
The company's return on equity has shrunk by 128% YoY
SUPN's return on invested capital has dropped by 115% year-on-year

Dividends

What is SUPN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SUPN.

Financial health

How did Supernus Pharmaceuticals financials performed over time
The company's total liabilities has shrunk by 57% YoY but it rose by 5% QoQ
SUPN's current ratio is up by 43% year-on-year
The debt is 96% smaller than the equity
The debt has dropped by 94% year-on-year
Supernus Pharmaceuticals's debt to equity has plunged by 93% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.